AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio
AbbVie announced its largest-ever ESMO data program, with new and updated results across seven solid tumor assets spanning lung, colorectal, ovarian, prostate and gastric cancers at the October 23-27 congress in Madrid. Standout results include Temab-A's 63% ORR in EGFR-mutant NSCLC and 14.7-month median OS in colorectal cancer vs 10.2 months for standard of care, plus ABBV-706's 56% ORR in relapsed/refractory SCLC.
Key figures
- Drug Name
- Temab-A (telisotuzumab adizutecan)
- Phase Of Trial
- Phase 1 (with ongoing Phase 3 AndroMETa-CRC-560, AndroMETa-Lung-167, AMUR-Lung-01)
- Temab a crc orr
- 30%
- Abbv 706 median os
- 12.4 months
- Abbv 706 2l only orr
- 82%
- Temab a crc median os
- 14.7 months vs 10.2 months standard of care
- Abbv 1480 1l nsclc orr
- 61.9%
- Abbv 1480 1l median pfs
- 15.2 months
- Abbv 706 2l plus sclc orr
- 56%
- Temab a nsclc egfr wt orr
- 50%
- Temab a nsclc egfr mut orr
- 63%
- Abbv 1480 docetaxel combo orr
- 66.7%
- Abbv 969 ctdna reduction 50pct
- 90%
- Temab a brain met Intracranial ORR
- 37%
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.